Oxford Biomedica plc (LON:OXB – Get Free Report) insider Heather Preston purchased 11,389 shares of the business’s stock in a transaction dated Tuesday, June 17th. The shares were purchased at an average price of GBX 324 ($4.40) per share, for a total transaction of £36,900.36 ($50,075.13).
Oxford Biomedica Stock Performance
OXB traded down GBX 4.50 ($0.06) during mid-day trading on Tuesday, reaching GBX 318 ($4.32). 31,308 shares of the company traded hands, compared to its average volume of 256,236. The stock has a market capitalization of £338.04 million, a P/E ratio of -2.36 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. Oxford Biomedica plc has a 52-week low of GBX 232.50 ($3.16) and a 52-week high of GBX 455 ($6.17). The company’s fifty day moving average price is GBX 304.26 and its 200-day moving average price is GBX 348.84.
Oxford Biomedica (LON:OXB – Get Free Report) last issued its earnings results on Wednesday, April 9th. The biopharmaceutical company reported GBX (41.75) (($0.57)) earnings per share for the quarter. Oxford Biomedica had a negative return on equity of 202.50% and a negative net margin of 145.98%. On average, sell-side analysts expect that Oxford Biomedica plc will post -31.0799998 EPS for the current year.
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.
Featured Stories
- Five stocks we like better than Oxford Biomedica
- Find and Profitably Trade Stocks at 52-Week Lows
- Lululemon, UNH, Enphase: Bad News, Good Opportunity?
- What does consumer price index measure?
- Applied Digital: Now the High-Stakes Race to Build Begins
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Zscaler Upgraded: Wall Street Forecasts 26% More Upside
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.